Immunotherapy Stocks List

Symbol Grade Name % Change
CLDX C Celldex Therapeutics, Inc. -2.88
FBIO D Fortress Biotech, Inc. -0.25
CDMO C Avid Bioservices, Inc. -6.31
CVM C Cel-Sci Corporation -5.73
BTX C Brooklyn ImmunoTherapeutics, Inc. -21.92
IMUX F Immunic, Inc. -1.26
GNCA F Genocea Biosciences, Inc. -7.55
ATNM F Actinium Pharmaceuticals, Inc. 2.34
ENLV D Enlivex Therapeutics Ltd. -1.62
DBVT B DBV Technologies S.A. -1.54
APTO D Aptose Biosciences, Inc. -10.38
BLCM F Bellicum Pharmaceuticals, Inc. -2.87
IOVA F Iovance Biotherapeutics, Inc. -3.15
CDTX F Cidara Therapeutics, Inc. -2.88
ADAP D Adaptimmune Therapeutics plc -4.30
ONCS F OncoSec Medical Incorporated -8.25
CLBS F Caladrius Biosciences, Inc. -1.90
ALPN D Alpine Immune Sciences, Inc. 2.58
IBRX D ImmunityBio, Inc. -0.32
PDSB C PDS Biotechnology Corporation -17.61
CNCR D Loncar Cancer Immunotherapy ETF -0.78
SELB F Selecta Biosciences, Inc. -3.62
MRKR C Marker Therapeutics, Inc. -2.43
JNCE F Jounce Therapeutics, Inc. -1.99
URGN D UroGen Pharma Ltd. -3.67
ARGX F argenx SE -0.47
IMRN F Immuron Limited 0.75
MBIO F Mustang Bio, Inc. -2.30
FBIOP A Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock 1.68
CDMOP D Avid Bioservices, Inc. - 10.50% Series E Convertible Preferred Stock 0.00
SURF F Surface Oncology, Inc. 2.84
IMV F IMV Inc. -2.55
REPL B Replimune Group, Inc. 8.79
ARDS D Aridis Pharmaceuticals Inc. 2.11
GRTS F Gritstone Oncology, Inc. -2.63
AVCO F Avalon GloboCare Corp. 3.07
INMB F INmune Bio Inc. -0.72
HARP B Harpoon Therapeutics, Inc. -3.02
TCRR F TCR2 Therapeutics Inc. -2.11
DTIL F Precision BioSciences, Inc. -5.56
NXTC F NextCure, Inc. -3.88
LCTX B Lineage Cell Therapeutics, Inc. 7.36
IPHA F Innate Pharma S.A. -2.34
THMO F ThermoGenesis Holdings, Inc. -4.74
ORIC F Oric Pharmaceuticals, Inc. -1.27
ADTX F ADiTx Therapeutics, Inc. 0.72
IMTX D Immatics N.V. -1.33
NKTX F Nkarta, Inc. -4.63
PAND A Pandion Therapeutics Inc. 0.00
CMPI F Checkmate Pharmaceuticals, Inc. -1.77
HGEN C Humanigen, Inc. 5.43
GLSI C Greenwich LifeSciences, Inc. 5.31
ONCR C Oncorus, Inc. 0.53
NBTX F Nanobiotix S.A. -2.01
SNSE F Sensei Biotherapeutics, Inc. 0.00
EVAX D Evaxion Biotech A/S -3.16
IMCR D Immunocore Holdings plc 0.40
ADAG F Adagene Inc. -2.12
NEXI F NexImmune, Inc. 1.46
BCTX D BriaCell Therapeutics Corp. -1.45
CNTB C Connect Biopharma Holdings Limited 4.08
View As Page of Charts

Recent Signals

Date Stock Signal Type

Recent News for Immunotherapy Stocks

Date Stock Title
May 5 IOVA Iovance Biotherapeutics Q1 Earnings Preview
May 5 DBVT DBV Technologies Announces Filing of its First Form 10-Q for the First Quarter of 2021
May 5 HGEN This Biotech Stock Could See A Big Move If It Breaks Out Of The Pennant It's Forming
May 5 INMB INmune Bio EPS misses by $0.05
May 5 INMB INmune Bio, Inc. Announces First Quarter 2021 Results and Provides Business Update
May 5 NXTC NextCure to Present at the BofA Securities 2021 Virtual Health Care Conference
May 5 REPL Replimune shares rise 9% following positive clinical trial updates for lead candidate
May 5 CDTX Cidara Therapeutics (CDTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
May 5 HGEN Humanigen is on the rise after publication of Phase 3 data for COVID-19 therapy
May 5 HGEN Humanigen Announces Publication of Results From Phase 3 Randomized Double-Blind Placebo-Controlled Study Demonstrating the Efficacy and Safety of Lenzilumab™ in Hospitalized COVID-19 Patients
May 5 JNCE Jounce Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 5 SNSE Sensei Biotherapeutics Appoints Maura Gillison, M.D., Ph.D., and Richard Ulevitch, Ph.D., to its Immuno-Oncology Advisory Board
May 5 LCTX Lineage Announces Appointment of Anula Jayasuriya, M.D., PH.D., M.B.A., to Board of Directors
May 5 IMCR What You Need To Know About Immunocore Holdings plc's (NASDAQ:IMCR) Investor Composition
May 5 REPL Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo® (cemiplimab) for the Treatment of CSCC & Evaluating RP1 in Combination with Opdivo® (nivolumab) in anti-PD1 Failed Melanoma
May 5 SURF Surface Oncology EPS beats by $0.04, beats on revenue
May 5 SURF Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2021
May 5 EVAX What Kind Of Investors Own Most Of Evaxion Biotech A/S (NASDAQ:EVAX)?
May 5 ALPN What Type Of Shareholders Make Up Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Share Registry?
May 4 APTO Aptose Biosciences Inc. (APTO) CEO William Rice on Q1 2021 Results - Earnings Call Transcript

Immunotherapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.

In recent years, immunotherapy has become of great interest to researchers, clinicians and pharmaceutical companies, particularly in its promise to treat various forms of cancer.Immunomodulatory regimens often have fewer side effects than existing drugs, including less potential for creating resistance when treating microbial disease.Cell-based immunotherapies are effective for some cancers. Immune effector cells such as lymphocytes, macrophages, dendritic cells, natural killer cells (NK Cell), cytotoxic T lymphocytes (CTL), etc., work together to defend the body against cancer by targeting abnormal antigens expressed on the surface of tumor cells.
Therapies such as granulocyte colony-stimulating factor (G-CSF), interferons, imiquimod and cellular membrane fractions from bacteria are licensed for medical use. Others including IL-2, IL-7, IL-12, various chemokines, synthetic cytosine phosphate-guanosine (CpG) oligodeoxynucleotides and glucans are involved in clinical and preclinical studies.

More about Immunotherapy
Browse All Tags